Pancreatic Cancer Diagnostic

Global Pancreatic Cancer Diagnostic Market to Reach US$3.6 Billion by 2030

The global market for Pancreatic Cancer Diagnostic estimated at US$2.6 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Pancreatic Cancer Diagnostic Consumables, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Pancreatic Cancer Diagnostic Instruments segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$710.6 Million While China is Forecast to Grow at 8.8% CAGR

The Pancreatic Cancer Diagnostic market in the U.S. is estimated at US$710.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$726.2 Million by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Pancreatic Cancer Diagnostics Market – Key Trends & Drivers Summarized

Why Is Pancreatic Cancer Diagnostics a Growing Healthcare Priority?

The pancreatic cancer diagnostics market is expanding rapidly due to the increasing global incidence of pancreatic cancer, one of the most aggressive and difficult-to-detect malignancies. Late-stage diagnoses and poor survival rates have intensified the need for early and more accurate diagnostic solutions. Advancements in imaging, biomarker testing, and liquid biopsy technologies are significantly improving early detection capabilities, leading to better patient outcomes.

Additionally, the rising geriatric population and growing awareness of genetic predisposition to pancreatic cancer are driving demand for screening programs and diagnostic innovations. Government funding and private investments in cancer research are further accelerating market expansion.

How Are Liquid Biopsy and AI-Driven Diagnostics Transforming Detection?

The adoption of liquid biopsy techniques is revolutionizing pancreatic cancer diagnostics by enabling non-invasive detection of circulating tumor DNA (ctDNA) and exosomal markers. Liquid biopsy offers the potential for earlier diagnosis, real-time monitoring, and personalized treatment planning, reducing reliance on invasive biopsy procedures.

AI-powered imaging and machine learning algorithms are also enhancing diagnostic accuracy by analyzing CT scans, MRI data, and histopathology slides more efficiently. AI-driven predictive models are identifying subtle patterns in imaging data, aiding early-stage pancreatic cancer detection and risk assessment.

Is Precision Medicine and Genetic Testing Expanding Market Opportunities?

The integration of precision medicine into pancreatic cancer diagnostics is expanding market opportunities. Genetic testing for BRCA1, BRCA2, and other hereditary mutations is helping identify individuals at high risk, enabling proactive screening and personalized treatment strategies. Companion diagnostics linked to targeted therapies, such as PARP inhibitors and immunotherapies, are further driving demand for advanced molecular testing.

Additionally, multi-omic approaches that combine genomics, proteomics, and metabolomics are improving diagnostic accuracy, paving the way for more effective and tailored treatment plans. As personalized medicine continues to evolve, demand for advanced pancreatic cancer diagnostics is expected to rise.

What’s Driving the Growth of the Pancreatic Cancer Diagnostics Market?

The growth in the pancreatic cancer diagnostics market is driven by increasing disease prevalence, advancements in liquid biopsy and AI-powered imaging, and the expanding role of genetic testing in early detection. The rising adoption of precision medicine and companion diagnostics is further shaping market trends.

Additionally, government and private sector investments in cancer research, coupled with the development of innovative diagnostic biomarkers, are fueling market expansion. As early detection remains critical in improving survival rates, the pancreatic cancer diagnostics market is poised for continued growth.

SCOPE OF STUDY:

The report analyzes the Pancreatic Cancer Diagnostic market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Pancreatic Cancer Diagnostic Consumables, Pancreatic Cancer Diagnostic Instruments, Pancreatic Cancer Diagnostic Services); Test Type (Imaging Test, Biopsy Test, Blood Test, Other Test Types); Cancer Type (Exocrine Cancer, Endocrine Cancer); End-Use (Hospitals End-Use, Laboratories End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• Apexigen
• AstraZeneca
• Boston Scientific
• Canon Medical Systems Corporation
• ClearNote Health
• Epic Sciences
• Exact Sciences Corp.
• FUJIFILM Holdings Corporation
• GRAIL
• Guardant Health
• Immunovia
• Myriad Genetics
• NeoGenomics Laboratories
• Novartis
• Pfizer
• Prestige Biopharma
• Roche
• Seagen
• Siemens Healthineers

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.